Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-10-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股子公司中标河北省孕妇耳聋基因检测服务项目的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Co., Ltd. regarding its controlling subsidiary winning a bid for a gene testing service project. It details the project name, parties involved, contract period, budget amount, and the potential impact on the company. There are no financial statements, no detailed financial performance data, nor is this a report or transcript. It is a regulatory announcement about a contract win, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update or Earnings Release. The document length is short and it is an announcement rather than a report or presentation.
2020-10-26 Chinese
关于向特定对象发行股票摊薄即期回报、采取填补措施（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding a specific issuance of shares to certain investors. It discusses the dilution of immediate returns due to this issuance, the impact on key financial indicators, assumptions used for projections, the necessity and rationale for the issuance, the use of raised funds, risk warnings, and measures to mitigate dilution effects. It also includes commitments from controlling shareholders, directors, and senior management regarding the fulfillment of these measures. The document references regulatory guidelines and approval processes from the Shenzhen Stock Exchange and China Securities Regulatory Commission. The content focuses on capital raising activities, share issuance, and related financial impacts rather than being a full financial report or earnings release. It is not a full annual or interim report, nor a simple announcement of a report publication. The document is comprehensive and substantive, not a brief notice or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes such as this specific share issuance to certain investors.
2020-10-26 Chinese
关于公司向特定对象发行股票预案修订情况说明的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the revision of a company's plan for a private placement of shares to specific investors. It details changes in the issuance plan, including adjustments to the amount of funds to be raised and updates on the approval process. The document references regulatory compliance and provides a summary of the revised issuance plan. It does not contain actual financial statements or detailed financial results but rather updates on a capital raising activity. The document length is short (1485 characters) and it is an announcement about a financing plan revision, not the full financing report itself. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-10-26 Chinese
向特定对象发行股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "向特定对象发行股票预案" which translates to "Proposal for Private Placement of Shares to Specific Investors." It is issued by Shenzhen BGI Genomics Co., Ltd. The content includes detailed information about the issuance plan, background, purpose, pricing, number of shares, use of proceeds, regulatory approvals required, and risk disclosures. It also references approvals by the board and shareholders, regulatory bodies such as the Shenzhen Stock Exchange and China Securities Regulatory Commission, and includes detailed financial and operational analysis related to the issuance. This is a comprehensive document outlining a capital raising activity through a private placement of shares to specific investors. It is not a simple announcement or a brief summary but a full plan document with detailed disclosures and analysis. Therefore, it fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed content confirm it is not a mere announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2020-10-26 Chinese
向特定对象发行股票方案论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 向特定对象发行股票方案论证分析报告（修订稿）" which translates to "Shenzhen BGI Co., Ltd. Private Placement of Shares Proposal Demonstration and Analysis Report (Revised)". The content extensively discusses the background, purpose, legal compliance, pricing, and fairness of a private placement of shares (向特定对象发行股票). It includes detailed analysis of the issuance plan, regulatory compliance, pricing methods, and impact on shareholders. There is no indication that this is a full annual or quarterly financial report, audit report, earnings release, or other types of filings. Instead, it is a detailed report supporting a capital raising activity through a private placement of shares. This fits the category of "Capital/Financing Update" (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2020-10-26 Chinese
关于调整公司向特定对象发行股票方案的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding an adjustment to its plan for a private placement of shares to specific investors. It details changes in the amount of funds to be raised and the allocation of those funds. The document references board and shareholder meetings approving the plan and mentions that the plan requires regulatory approval before implementation. The text is about a financing activity involving issuance of shares to specific parties, which fits the category of Capital/Financing Update. The document length is 2120 characters, which is relatively short but contains substantive information about the financing plan adjustment, not just a notice of report publication or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-10-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.